Arecor Therapeutics plc (AREC.L)

120,00 0,00 (0,00%) Alla chiusura: 02:11PM BST

Arecor Therapeutics plc

Chesterford Research Park
Little Chesterford CB10 1XL
United Kingdom
44 1223 426 060
https://arecor.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 50

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sarah Jennifer Howell Ph.D.	CEO & Director	439k	N/D	1975
Ms. Susan Day Lowther FCMA	CFO, Company Secretary & Director	322k	N/D	1960
Dr. Jan Jezek Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Mr. David Gerring	Senior Vice President of Development	N/D	N/D	N/D
Dr. Manjit Rahelu Ph.D.	Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Arecor Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.